Jump-starting cheaper cancer vaccines

September 26, 2012
Dendritic cells (top left), derived from human embryonic stem cells, could provide an economical route to produce human cancer therapeutics. Credit: iStockphoto.com/drliwa (main image)

Dendritic cells (DCs)—workhorses of the immune system—derived from human embryonic stem cells (hESCs) may provide an economical way of generating off-the-shelf therapeutic vaccines against cancers, according to research led by Jieming Zeng and Shu Wang from the A*STAR Institute of Bioengineering and Nanotechnology, Singapore.

DCs process and present antigens—substances that stimulate immune responses—to other cells of the immune system that will then eliminate pathogenic cells carrying these antigens. This ability makes DCs ideal as vaccines within the body. As such, the US recently approved the first DC-based vaccine for use. DCs sourced from another individual, however, may be attacked by the immune system of a recipient. Consequently, DC-based vaccines have been prepared using cells derived from the recipient's own body. This is expensive, the supply of cells is limited, and highly variable results have complicated the evaluation of clinical trials.

Using hESCs, however, it is possible to produce a steady supply of DCs in unlimited numbers, under strict quality control. But, since these DCs are still susceptible to , Zeng, Wang and co-workers enlisted the aid of invariant natural killer T (iNKT) cells. These cells can be stimulated by compounds attached to molecules of the glycoprotein CD1d and used to boost the activity of DCs, thereby enabling them to trigger the immune response before being eliminated.

First the researchers added genes to DCs generated from hESCs to produce extra CD1d. The greater amount of this glycoprotein produced by the cells then triggered an expansion of iNKT cells in the presence of α-galactosylceramide (α-GC), a ligand or compound which binds to iNKT cells.

Subsequently, they found that α-GC was unnecessary for inducing an anti-. This is advantageous because previous studies by others with mice had shown that using α-GC for this purpose can lead to uncontrolled iNKT activation. In fact, the researchers showed that pulsing the modified DCs with melanoma antigen was sufficient to prime immune T cells against melanoma tumor cells. The same strategy worked with DCs derived from human monocytes, a type of white blood cell.

"The ability to generate large amounts of uniform hESC-DCs competent in inducing antitumor immunity indicates that they could be used as an unlimited cell source to produce off-the-shelf DC vaccines, to overcome the drawbacks of using an individual's own cells," Wang says. "We are now focusing on developing a simpler process to produce DCs with similar or even better capabilities."

Explore further: Scientists discover dendritic cells key to activating human immune responses

More information: Zeng, J., Shahbazi, M., Wu, C., Toh, H. C. & Wang, S. Enhancing immunostimulatory function of human embryonic stem cell-derived dendritic cells by CD1d overexpression. The Journal of Immunology 188, 4297–4304 (2012). www.jimmunol.org/content/188/9/4297

Related Stories

Scientists discover dendritic cells key to activating human immune responses

July 16, 2012
Scientists at A*STAR’s Singapore Immunology Network (SIgN), in collaboration with Newcastle University, UK, the Singapore Institute of Clinical Sciences and clinicians from multiple hospitals in Singapore, have identified ...

Rare immune cell is asset and liability in fighting infection

August 26, 2011
The same trait that makes a rare immune cell invaluable in fighting some infections also can be exploited by other diseases to cause harm, two new studies show.

Dendritic cell subtype protects against atherosclerosis

November 10, 2011
Atherosclerosis, commonly referred to as "hardening of the arteries," is a major risk factor for heart attack and stroke. The cause of atherosclerosis is not well understood but, for some time, chronic inflammatory immune ...

Recommended for you

Genetic immune deficiency could hold key to severe childhood infections

July 18, 2017
A gene mutation making young children extremely vulnerable to common viruses may represent a new type of immunodeficiency, according to a University of Queensland researcher.

What are the best ways to diagnose and manage asthma?

July 18, 2017
What are the best ways to diagnose and manage asthma in adults? This can be tricky because asthma can stem from several causes and treatment often depends on what is triggering the asthma.

Large multi-ethnic study identifies many new genetic markers for lupus

July 17, 2017
Scientists from an international consortium have identified a large number of new genetic markers that predispose individuals to lupus.

Study finds molecular explanation for struggles of obese asthmatics

July 17, 2017
A large, bouquet-shaped molecule called surfactant protein A, or SP-A, may explain why obese asthma patients have harder-to-treat symptoms than their lean and overweight counterparts, according to a new study led by scientists ...

Team identifies potential cause for lupus

July 14, 2017
Leading rheumatologist and Feinstein Institute for Medical Research Professor Betty Diamond, MD, may have identified a protein as a cause for the adverse reaction of the immune system in patients suffering from lupus. A better ...

Immunosuppression underlies resistance to anti-angiogenic therapy

July 14, 2017
A Massachusetts General Hospital (MGH) research team has identified a novel mechanism behind resistance to angiogenesis inhibitors - drugs that fight cancer by suppressing the formation of new blood vessels. In their report ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.